A PYMNTS Company

US: Yet another multibillion-dollar pharma merger announced

 |  June 9, 2014

As the world’s pharmaceutical industry continues to see an influx of consolidation, reports say the latest merger was announced when Merck and Idenix Pharmaceuticals revealed plans to combine in a $3.85 billion deal.

According to a press release, the transaction has already been approved by the boards of directors for both firms. Merck plans to boost its hepatitis C treatment portfolio through acquiring Idenix, the company said.

The transaction agreed upon includes the launch of a tender offer to acquire Idenix through one of Merck’s subsidiaries. The deal remains subject to regulatory approval as well.

Full content: Market Watch

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.